FDA Announces Recall of Over 20 Million Eggs After Salmonella Outbreak in 7 States
On June 6, 2025, the U.S. Food and Drug Administration (FDA) announced that August Egg Company of Hilmar, California, is recalling over 1,700,000 dozen brown cage-free and brown certified organic eggs, totaling over 20 million eggs. The recall was initiated in response to an ongoing investigation by the FDA and the Centers for Disease Control and Prevention (CDC) into a multistate outbreak of Salmonella that has sickened 79 people and resulted in 21 hospitalizations so far.
While the eggs were produced by August Egg Company, they were sold under multiple brand names at restaurants and retailers. This recall includes eggs sold in 6-, 12-, and 18-count packs as well as larger restaurant boxes under the following brand names: Clover, First Street, Nulaid, O Organics, Marketside, Raley's, Simple Truth, Sun Harvest, and Sunnyside.
The recalled eggs were distributed from Feb. 3, 2025, through May 6, 2025, to Walmart locations in nine states: Arizona, California, Illinois, Indiana, Nebraska, Nevada, New Mexico, Washington, and Wyoming, These eggs have "sell by" dates ranging from March 4, 2025, to June 4, 2025.
The eggs were also distributed from Feb. 3, 2025, through May 15, 2025, to several retailers in California and Nevada, including Save Mart, FoodMaxx, Lucky, Smart & Final, Safeway, Raley's, Food 4 Less, and Ralphs. These eggs have "sell by" dates ranging from March 4, 2025, to June 19, 2025.
At this time, the Salmonella outbreak investigation is ongoing, with illnesses reported in seven states: Arizona, California, Kentucky, Nebraska, Nevada, New Jersey, and Washington. The FDA is working to determine if the eggs were distributed to any other retailers in additional states. The recall may be updated as more information becomes available.
You can identify the recalled eggs by checking the side of the carton. The recalled eggs feature a printed Julian Date on the side between '32' and '126' followed by a plant code number 'P-6562' or 'CA-5330' on the egg carton or package. The recalled eggs sold to consumers are packed in fiber or plastic cartons, with the above codes printed on one side of the carton.
Here is a full list of the recalled eggs, along with their identifying information:
Item Name
Plant Number
Carton UPC
Clover Organic Large Brown 12 eggs
P-6562 or CA-5330
070852010427
First Street Cage Free Large Brown Loose (1 case = 150 eggs)
P-6562 or CA-5330
041512039638
Nulaid Medium Brown Cage Free 12 eggs
P-6562 or CA-5330
071230021042
Nulaid Jumbo Brown Cage Free 12 eggs
P-6562 or CA-5330
071230021011
O Organics Cage Free Large Brown 6 eggs
P-6562 or CA-5330
079893401522
O Organics Large Brown 12 eggs
P-6562 or CA-5330
079893401508
O Organics Large Brown 18 eggs
P-6562 or CA-5330
079893401546
Marketside Organic Large Cage Free Brown 12 eggs
P-6562 or CA-5330
681131122771
Marketside Organic Large Cage Free Brown 18 eggs
P-6562 or CA-5330
681131122801
Marketside Large Cage Free Brown 12 eggs
P-6562 or CA-5330
681131122764
Marketside Large Cage Free Brown 18 eggs
P-6562 or CA-5330
681131122795
Raley's Large Cage Free Brown 12 eggs
P-6562 or CA-5330
046567033310
Raley's Large Cage Free Brown 18 eggs
P-6562 or CA-5330
046567040325
Raley's Organic Large Cage Free Brown 12 eggs
P-6562 or CA-5330
046567028798
Raley's Organic Large Cage Free Brown 18 eggs
P-6562 or CA-5330
046567040295
Simple Truth Medium Brown Cage Free 18 eggs
P-6562 or CA-5330
011110099327
Simple Truth Large Brown Cage Free 18 eggs
P-6562 or CA-5330
011110873743
Sun Harvest Organic Cage Free Large Brown 12 eggs
P-6562 or CA-5330
041512131950
Sun Harvest Organic Cage Free Large Brown 18 eggs
P-6562 or CA-5330
041512145162
Sunnyside Large Brown Cage Free 12 eggs
P-6562 or CA-5330
717544211747
Sunnyside Large Brown Cage Free 18 eggs
P-6562 or CA-5330
717544211754
Sunnyside Organic Cage Free Large Brown 12 eggs
P-6562 or CA-5330
717544201441
Sunnyside Organic Cage Free Large Brown 18 eggs
P-6562 or CA-5330
717544211761
Loose Small Brown Cage Free (1 box = 6 flats) (1 flat = 30 eggs)
P-6562 or CA-5330
NA
Loose Medium Brown Cage Free (1 box = 6 flats) (1 flat = 30 eggs)
P-6562 or CA-5330
NA
Loose Medium Brown Organic (1 box = 6 flats) (1 flat = 30 eggs)
P-6562 or CA-5330
NA
Loose Large Brown Organic (1 box = 6 flats) (1 flat = 30 eggs)
P-6562 or CA-5330
NA
Loose Jumbo Brown Cage Free (1 box = 5 flats) (1 flat = 20 eggs)
P-6562 or CA-5330
NA
Loose Jumbo Brown Organic (1 box = 5 flats) (1 flat = 20 eggs)
P-6562 or CA-5330
NA
You can also view photos of the labels on the FDA website.
The recalled eggs are no longer in stores, but the FDA is concerned they may still be in consumers' homes. Per FDA guidance, check your refrigerators for the recalled brown cage-free and brown certified organic eggs. If you have the recalled eggs, throw them away or return them to the original place of purchase for a full refund.
If you stored the eggs without their original packaging and can't tell if they are part of this outbreak, the FDA urges you to discard them out of an abundance of caution. Additionally, be sure to carefully clean and sanitize any surfaces that may have come in contact with the contaminated eggs.
Further questions about this recall may be directed to August Egg Company at 1-800-710-2554, between 9 a.m. and 5 p.m. PT.
If you believe you have already consumed the recalled eggs, you should monitor yourself for symptoms of a Salmonella infection. The most common symptoms include diarrhea, stomach cramps, dehydration, vomiting, and fever higher than 102°F—and, typically, symptoms begin between six hours and six days after eating the contaminated food. If you're experiencing any of those symptoms, contact your healthcare provider.
While most individuals feel better after four to seven days, Salmonella can cause serious infections in children, older individuals, and those with weakened immune systems. To learn more about Salmonella, visit the CDC website.
Read the original article on ALLRECIPES
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
32 minutes ago
- Newsweek
Mushroom Recall Sparks Nationwide Warning to Customers
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Hofood99 Inc. is recalling packages of their Enoki Mushrooms due to fears the product may be contaminated with listeria. Newsweek reached out to the company via phone for additional comment on Wednesday and left a voicemail. Why It Matters Numerous recalls have been initiated this year due to the potential for the following: damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or food allergies every year. According to the Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. The FDA warns that Listeria monocytogenes is an organism that could cause serious and sometimes fatal infections in frail or older people, young children and those with weakened immune systems. Listeria could also lead to stillbirths or miscarriages in pregnant women, the FDA says. What To Know According to the FDA alert, the mushrooms were distributed nationwide to stores and retailers. The recalled mushrooms are sold in 200-gram green plastic packaging with a with UPC Barcode of 6 976532 310051 seen on the back label. No illnesses or injuries have been reported related to the recalled mushrooms. The mushrooms were distributed by Hofood99 Inc., located at 21903 56th Avenue Oakland Gardens, New York 11364. Recalled packages of Enoki Mushroom from Hofood99 Inc. can be seen in a June 11, 2025, recall alert. (Photo from the U.S. Food and Drug Administration) Recalled packages of Enoki Mushroom from Hofood99 Inc. can be seen in a June 11, 2025, recall alert. (Photo from the U.S. Food and Drug Administration) What People Are Saying The FDA in the alert in part: "The contamination was discovered after samples were collected from a store in Michigan and subsequent analysis by Michigan Department of Agriculture & Rural Development (MDARD) Laboratory Division revealed the presence of Listeria monocytogenes." In an email to Newsweek in January, the FDA said: "Most recalls in the U.S. are carried out voluntarily by the product manufacturer and when a company issues a public warning, typically via news release, to inform the public of a voluntary product recall, the FDA shares that release on our website as a public service. "The FDA's role during a voluntary, firm-initiated, recall is to review the recall strategy, evaluate the health hazard presented by the product, monitor the recall, and as appropriate alert the public and other companies in the supply chain about the recall," the FDA continued. It added: "The FDA provides public access to information on recalls by posting a listing of recalls according to their classification in the FDA Enforcement Report, including the specific action taken by the recalling company. The FDA Enforcement Report is designed to provide a public listing of products in the marketplace that are being recalled." Additional information on recalls can be found via the FDA's Recalls, Market Withdrawals, & Safety Alerts. What Happens Next Customers who have purchased the recalled mushrooms may return the product to the original place of purchase for a full refund or destroy it, the FDA says. People with additional questions may contact the company at (917) 756-9833 weekdays from 9 a.m. to 2 p.m.
Medscape
2 hours ago
- Medscape
Taletrectinib Approved for NSCLC
The FDA has approved taletrectinib (Ibtrozi, Nuvation Bio) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in first- and later-line settings, regardless of prior ROS1 tyrosine kinase inhibitor (TKI) exposure. Taletrectinib is considered a next-generation ROS1 TKI to distinguish it from two first-generation products already on the US market: crizotinib and entrectinib. A third ROS1 TKI approved in 2023, repotrectinib, is also a next-generation medicine. Like repotrectinib, FDA granted taletrectinib a breakthrough therapy designation. Compared with crizotinib and entrectinib, Nuvation Bio data suggests taletrectinib has greater brain penetration, lower incidence of neurologic adverse events, less likelihood of resistance, and other benefits, plus a possible safety and efficacy edge over next-generation rival repotrectinib. 'Taletrectinib will likely become the preferred treatment option for advanced ROS1+ NSCLC,' commented Thomas E. Stinchcombe, MD, an associate editor at the Journal of Clinical Oncology , in the 'Context' section of his journal's publication of a pooled analysis of Nuvation Bio's two approval studies, TRUST-I and TRUST-II, in April. Taletrectinib was originally developed in China and was approved there in Jan 2025 for the same indication granted by FDA. The company plans a US launch in mid-2025, they stated in a press release. About 2% of NSCLC patients have ROS1-positive disease, and about a third of them present with brain metastases. ROS1-positive patients have an oncogenic rearrangement in the ROS1 gene, which leads to an abnormal ROS1 fusion protein that drives cancer growth. ROS1 TKIs block the protein's activity. The drug's approval was based on results of TRUST-I and TRUST-II, phase 2, single-arm, open label studies in ROS1-positive NSCLC patients treated with oral taletrectinib 600 mg once daily until progression, unacceptable toxicity, death, or consent withdrawal. Of the 273 subjects in the pooled analysis, 93.8% had stage IV disease, 33.7% had brain metastases, and 27.1% had received chemotherapy. TRUST-I included Chinese subjects who were either new to TKIs or who had received crizotinib. TRUST-II included patients from North America, Europe, and Asia who were TKI-naive or who had been treated with crizotinib or entrectinib. The efficacy population included 157 patients (103 in TRUST-I; 54 in TRUST-II) who were naive to treatment with a ROS1 TKI and 113 patients (66 in TRUST-I; 47 in TRUST-II) who had received one prior ROS1 TKI. Patients may have received prior chemotherapy for advanced disease. For treatment-naive patients, the overall response rate (ORR) was 90% in TRUST-I and 85% in TRUST-II, with 72% and 63% of responders having a duration of response (DOR) of at least a year, respectively. For TKI-pretreated patients, ORR was 52% in TRUST-I and 62% in TRUST-II, with 74% and 83% of responders having a DOR of at least 6 months, respectively. Among 13 patients with a G2032R mutation, which triggers resistance to first generation ROS1 TKIs, eight (61.5%) had a response to taletrectinib. In a safety analysis with 352 patients, the most frequent treatment-emergent adverse events with taletrectinib were gastrointestinal problems (88%) and elevated aspartate aminotransferase (72%) and alanine aminotransferase (68%). Neurologic adverse events included dizziness (21%) and dysgeusia (15%). Overall, 33% of patients had grade 3 or higher treatment-related adverse events. Treatment-emergent adverse events led to discontinuation in 7% of patients. There were three treatment-related deaths due to abnormal hepatic function, liver failure, and pneumonia. Prescribing information for taletrectinib includes warnings and precautions for hepatotoxicity, interstitial lung disease/pneumonitis, QTc interval prolongation, hyperuricemia, myalgia with creatine phosphokinase elevation, skeletal fractures, and embryo-fetal toxicity. The recommended taletrectinib dose is 600 mg orally once daily on an empty stomach until disease progression or unacceptable toxicity. Taletrectinib pricing was not available, but fourteen 160 mg capsules of rival repotrectinib — the initial 2-week supply with daily dosages doubling afterwards — is $7,666.97, according to
Yahoo
2 hours ago
- Yahoo
Salami Recalled in Canada Due to Salmonella Outbreak—Here's What to Know
A salami recall in Canada, due to Salmonella, was just announced. The recall impacts Bona and Rea branded salami sold in three provinces. There are illnesses connected to this recall—contact a doctor if symptoms an active recall on three types of salami sold in multiple Canadian provinces, according to the Canadian Food Inspection Agency. This is due to a Salmonella contamination. The following are the brands and types of salami impacted by this recall. Note the UPC and additional codes printed on the affected products, though the recalled salami may have been sold at deli counters without the coded packaging: Brand Product UPC Codes Bona Mild Genova Salami N/A 5035 226 Rea Genoa Salami Sweet 8 41571 04226 2 5035 226; 5049 226 Rea Genoa Salami Hot 8 41571 04228 6 5020 228; 5035 228 The affected salami was sold in variable sizes at deli counters and grocery locations in Alberta, Manitoba and Ontario. Check your deli meat for the recall information or call your place of purchase to see if it matches the recall information. If so, dispose of it immediately. There are reported illnesses connected to this recall. Salmonella infection (salmonellosis) can cause short-term symptoms of foodborne illness like diarrhea, fever, headache, nausea, vomiting and abdominal cramps. If you are showing signs of salmonellosis after eating the recalled salami, contact a health care professional as soon as possible. For questions about this recall, contact the CFIA's toll-free number at 1-800-442-2342 or email information@ Read the original article on EATINGWELL
